| |
Capsimax 2 mg
|
Capsimax 4 mg
|
Placebo
|
|---|
|
Baseline variables
|
| |
N
|
Mean ± SD
|
N
|
Mean ± SD
|
N
|
Mean ± SD
|
|
Age
|
27
|
31.07 ± 12.02
|
22
|
28.86 ± 11.58
|
28
|
28.71 ± 10.57
|
|
Height
|
27
|
170.13 ± 9.49
|
22
|
170.17 ± 8.58
|
28
|
173.05 ± 11.11
|
|
Weight
|
27
|
79.02 ± 20.12
|
22
|
80.16 ± 16.80
|
28
|
83.51 ± 19.67
|
|
SBP
|
27
|
115.04 ± 14.75
|
22
|
117.95 ± 10.28
|
28
|
118.89 ± 10.02
|
|
DBP
|
27
|
70.22 ± 10.18
|
22
|
73.18 ± 8.02
|
28
|
72.89 ± 9.64
|
|
BMI
|
27
|
27.02 ± 5.88
|
22
|
27.42 ± 4.15
|
28
|
27.80 ± 6.01
|
|
Waist
|
25
|
86.84 ± 17.38
|
22
|
89.90 ± 12.44
|
25
|
94.58 ± 17.87
|
|
Hip
|
25
|
102.44 ± 17.35
|
22
|
106.83 ± 10.27
|
25
|
107.36 ± 12.85
|
|
WHR
|
25
|
0.85 ± 0.06
|
22
|
0.84 ± 0.08
|
25
|
0.88 ± 0.09
|
|
Covariates
|
|
Lean Mass
|
27
|
50,234.82 ± 14,130.64
|
22
|
52,153.33 ± 12,140.28
|
28
|
53,581.51 ± 14,316.47
|
|
Fat Mass
|
27
|
20,570.47 ± 11,206.61
|
22
|
19,903.67 ± 9337.78
|
28
|
20,960.33 ± 11,799.70
|
|
Protein Intake
|
26
|
82.52 ± 38.95
|
22
|
100.32 ± 68.52
|
27
|
88.66 ± 39.97
|
|
Carbohydrate Intake
|
26
|
239.61 ± 287.44
|
22
|
186.27 ± 70.64
|
27
|
188.05 ± 80.82
|
|
Fat Intake
|
26
|
66.67 ± 24.71
|
22
|
76.99 ± 34.58
|
27
|
77.75 ± 45.28
|
|
Serum Total-C
|
27
|
173.33 ± 27.97
|
22
|
168.36 ± 37.87
|
28
|
178.93 ± 42.75
|
- Total-C Total cholesterol; BMI Body mass index; SBP Systolic blood pressure; DBP Diastolic Blood Pressure; WHR Waist Hip Ratio
- 1) Main Effect Multivariate p (Wilks’ Lambda) = 0.7073 for Baseline Variables. Univariate Main Effect p-values in all instances were p > 0.05 and ranged from p = 0.3047 to p = 0.8695. 2) Main Effect Multivariate p (Wilks’ Lambda) = 0.0.8562 for Baseline Covariates. Univariate Main Effect p-values in all instances were p > 0.05 and ranged from p = 0.3540 to p = 0.9438. 3) Baseline covariates explained extraneous variance and increased statistical power. Covariates did not dramatically change mean outcomes. There were no baseline differences. 3) N Number of subjects
